Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CNTBBearishIndustry Newsnews

High materiality7/10

CNTB declines after mixed Phase 2 rademikibart data; Phase 3 strategy under review

Sep 15, 2026, 12:21 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Missed primary endpoint lowers near-term probability of Phase 3 success; stock already at 52-week low; upcoming COPD readout and FDA discussions are catalysts but uncertainty remains.

AI summary

What happened, with direct paths to the underlying reporting

Connect Biopharma released topline Phase 2 results for rademikibart in asthma. The primary endpoint missed statistical significance, although the therapy significantly improved a key lung function measure and had a favorable safety profile. With an upcoming Phase 2 COPD readout and FDA discussions on a Phase 3 plan, the stock faces near-term volatility and potential upside on clearer regulatory direction.

CNTB hits 52-week low after Phase 2 rademikibart topline results.
Primary endpoint missed significance; secondary endpoint showed lung function gains.
FDA Phase 3 alignment planned; COPD Phase 2 readout due later this month.
Safety profile favorable; no discontinuations or new safety signals.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.